Article Details
Retrieved on: 2025-03-01 18:11:29
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article focuses on Krystal Biotech's announcement regarding the European approval recommendation for VYJUVEK, a gene therapy for treating dystrophic epidermolysis bullosa, directly addressing genetic defects. Although titled 'Natural medicine,' the concept is not present in the content, which emphasizes biotechnology advancements. Tags like 'Genodermatoses' and 'Gene therapy' align with the content's focus on genetic condition treatment.
Article found on: markets.businessinsider.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here